Carsten Wrenger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/472407/publications.pdf

Version: 2024-02-01

106	2,172	218677	276875
papers	citations	26 h-index	41 g-index

115	115	115	2692
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Natural Products as a Source for Treating Neglected Parasitic Diseases. International Journal of Molecular Sciences, 2013, 14, 3395-3439.	4.1	122
2	Analysis of the Vitamin B6 Biosynthesis Pathway in the Human Malaria Parasite Plasmodium falciparum. Journal of Biological Chemistry, 2005, 280, 5242-5248.	3.4	88
3	In the Human Malaria Parasite Plasmodium falciparum,Polyamines Are Synthesized by a Bifunctional Ornithine Decarboxylase,S-Adenosylmethionine Decarboxylase. Journal of Biological Chemistry, 2000, 275, 8097-8102.	3.4	82
4	The human malaria parasite Plasmodium falciparum has distinct organelle-specific lipoylation pathways. Molecular Microbiology, 2004, 53, 103-113.	2.5	74
5	Strategy to sequence the genome of Corynebacterium glutamicum ATCC 13032: use of a cosmid and a bacterial artificial chromosome library. Journal of Biotechnology, 2002, 95, 25-38.	3.8	70
6	Assessing the polyamine metabolism of Plasmodium falciparum as chemotherapeutic target. Molecular and Biochemical Parasitology, 2008, 160, 1-7.	1.1	64
7	Diseaseâ€specific biomarker discovery by aptamers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2009, 75A, 727-733.	1.5	64
8	Apicoplast Lipoic Acid Protein Ligase B Is Not Essential for Plasmodium falciparum. PLoS Pathogens, 2007, 3, e189.	4.7	58
9	Vitamin B metabolism in Plasmodium falciparum as a source of drug targets. Trends in Parasitology, 2010, 26, 35-43.	3.3	58
10	The Plasmodium falciparum Bifunctional Ornithine Decarboxylase, S-Adenosyl-l-methionine Decarboxylase, Enables a Well Balanced Polyamine Synthesis without Domain-Domain Interaction. Journal of Biological Chemistry, 2001, 276, 29651-29656.	3.4	52
11	Isocitrate dehydrogenase of Plasmodium falciparum. Energy metabolism or redox control?. FEBS Journal, 2003, 270, 1775-1783.	0.2	52
12	Poisoning Pyridoxal 5-Phosphate-Dependent Enzymes: A New Strategy to Target the Malaria Parasite Plasmodium falciparum. PLoS ONE, 2009, 4, e4406.	2.5	52
13	Harnessing the Helminth Secretome for Therapeutic Immunomodulators. BioMed Research International, 2014, 2014, 1-14.	1.9	45
14	Oxidative Stress Control by Apicomplexan Parasites. BioMed Research International, 2015, 2015, 1-10.	1.9	45
15	Identification of a mitochondrial superoxide dismutase with an unusual targeting sequence in Plasmodium falciparum. Molecular and Biochemical Parasitology, 2004, 137, 121-132.	1.1	44
16	Chemical and genetic validation of thiamine utilization as an antimalarial drug target. Nature Communications, 2013, 4, 2060.	12.8	44
17	Vitamin B1 de novo synthesis in the human malaria parasite Plasmodium falciparum depends on external provision of 4-amino-5-hydroxymethyl-2-methylpyrimidine. Biological Chemistry, 2006, 387, 41-51.	2.5	43
18	Specific Inhibition of the Aspartate Aminotransferase of Plasmodium falciparum. Journal of Molecular Biology, 2011, 405, 956-971.	4.2	42

#	Article	IF	Citations
19	The Uniqueness of the Trypanosoma cruzi Mitochondrion: Opportunities to Target New Drugs Against Chagas Disease. Current Pharmaceutical Design, 2011, 17, 2074-2099.	1.9	42
20	Recognition of biomarkers and cellâ€specific molecular signatures: Aptamers as capture agents. Journal of Separation Science, 2009, 32, 1523-1530.	2.5	41
21	Inflammasome activation and IL-1 signaling during placental malaria induce poor pregnancy outcomes. Science Advances, 2020, 6, eaax6346.	10.3	40
22	Parasite-specific inserts in the bifunctional S-adenosylmethionine decarboxylase/ornithine decarboxylase of Plasmodium falciparum modulate catalytic activities and domain interactions. Biochemical Journal, 2004, 377, 439-448.	3.7	38
23	Structural metal dependency of the arginase from the human malaria parasite Plasmodium falciparum. Biological Chemistry, 2005, 386, 117-26.	2.5	33
24	In vitro activity of extracts and isolated polyphenols from West African medicinal plants against Plasmodium falciparum. Parasitology Research, 2012, 111, 827-834.	1.6	32
25	Secretion of an acid phosphatase provides a possible mechanism to acquire host nutrients byPlasmodium falciparum. Cellular Microbiology, 2010, 12, 677-691.	2.1	27
26	The antioxidative effect of de novo generated vitamin B6 in Plasmodium falciparum validated by protein interference. Biochemical Journal, 2012, 443, 397-405.	3.7	27
27	Aptamers: Novel Molecules as Diagnostic Markers in Bacterial and Viral Infections?. BioMed Research International, 2013, 2013, 1-7.	1.9	26
28	Vitamin B1 and B6 in the malaria parasite: requisite or dispensable?. Brazilian Journal of Medical and Biological Research, 2008, 41, 82-88.	1.5	25
29	Melatonin activates <scp>FIS</scp>1, <scp>DYN</scp>1, and <scp>DYN</scp>2 Plasmodium falciparum relatedâ€genes for mitochondria fission: Mitoemeraldâ€<scp>GFP</scp> as a tool to visualize mitochondria structure. Journal of Pineal Research, 2019, 66, e12484.	7.4	25
30	Prognostic accuracy of MALDI-TOF mass spectrometric analysis of plasma in COVID-19. Life Science Alliance, 2021, 4, e202000946.	2.8	25
31	The Vitamin B1 Metabolism of Staphylococcus aureus Is Controlled at Enzymatic and Transcriptional Levels. PLoS ONE, 2009, 4, e7656.	2.5	24
32	Vitamin B6-Dependent Enzymes in the Human Malaria ParasitePlasmodium falciparum: A Druggable Target?. BioMed Research International, 2014, 2014, 1-11.	1.9	23
33	The ornithine decarboxylase domain of the bifunctional ornithine decarboxylase/S-adenosylmethionine decarboxylase of Plasmodium falciparum: recombinant expression and catalytic properties of two different constructs. Biochemical Journal, 2000, 352, 287-292.	3.7	22
34	MRSA Infections: From Classical Treatment to Suicide Drugs. Current Medicinal Chemistry, 2014, 21, 1809-1819.	2.4	22
35	HDL proteome remodeling associates with COVID-19 severity. Journal of Clinical Lipidology, 2021, 15, 796-804.	1.5	22
36	ADME Profiling in Drug Discovery and a New Path Paved on Silica. , 0, , .		20

#	Article	IF	Citations
37	The Assembly of the Plasmodial PLP Synthase Complex Follows a Defined Course. PLoS ONE, 2008, 3, e1815.	2.5	20
38	The apicomplexan parasite Toxoplasma gondii generates pyridoxal phosphate de novo. Molecular and Biochemical Parasitology, 2007, 152, 108-111.	1.1	19
39	Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structureâ€“activity relationship analyses. Future Medicinal Chemistry, 2017, 9, 135-151.	2.3	19
40	Filling the gap of intracellular dephosphorylation in the Plasmodium falciparum vitamin B1 biosynthesis. Molecular and Biochemical Parasitology, 2008, 157, 241-243.	1.1	18
41	Molecular Modeling Applied to Nucleic Acid-Based Molecule Development. Biomolecules, 2018, 8, 83.	4.0	18
42	Essential Metabolic Routes as a Way to ESKAPE From Antibiotic Resistance. Frontiers in Public Health, 2020, 8, 26.	2.7	18
43	Aspartate Aminotransferase - Bridging Carbohydrate and Energy Metabolism in Plasmodium Falciparum. Current Drug Metabolism, 2012, 13, 332-336.	1.2	15
44	Oligomeric interfaces as a tool in drug discovery: Specific interference with activity of malate dehydrogenase of Plasmodium falciparum in vitro. PLoS ONE, 2018, 13, e0195011.	2.5	15
45	Indole-3-glyoxyl tyrosine: synthesis and antimalarial activity against Plasmodium falciparum. Future Medicinal Chemistry, 2019, 11, 525-538.	2.3	15
46	Adverse pregnancy outcomes are associated with Plasmodium vivax malaria in a prospective cohort of women from the Brazilian Amazon. PLoS Neglected Tropical Diseases, 2021, 15, e0009390.	3.0	15
47	The ornithine decarboxylase domain of the bifunctional ornithine decarboxylase/S-adenosylmethionine decarboxylase of Plasmodium falciparum: recombinant expression and catalytic properties of two different constructs. Biochemical Journal, 2000, 352, 287.	3.7	14
48	The human malaria parasite Plasmodium falciparum expresses an atypical N-terminally extended pyrophosphokinase with specificity for thiamine. Biological Chemistry, 2006, 387, 1583-1591.	2.5	14
49	Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum. Biochemical Journal, 2013, 449, 175-187.	3.7	14
50	Trafficked Proteinsâ€”Druggable inPlasmodium falciparum?. International Journal of Cell Biology, 2013, 2013, 1-13.	2.5	14
51	Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Archives of Toxicology, 2018, 92, 1435-1451.	4.2	14
52	Targeting the vitamin biosynthesis pathways for the treatment of malaria. Future Medicinal Chemistry, 2013, 5, 769-779.	2.3	13
53	Point-of-care tests for malaria: speeding up the diagnostics at the bedside and challenges in malaria cases detection. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115122.	1.8	13
54	Aptamer Applications in Emerging Viral Diseases. Pharmaceuticals, 2021, 14, 622.	3.8	13

#	Article	IF	Citations
55	Crystal structure of truncated aspartate transcarbamoylase fromPlasmodium falciparum. Acta Crystallographica Section F, Structural Biology Communications, 2016, 72, 523-533.	0.8	12
56	DXS as a target for structure-based drug design. Future Medicinal Chemistry, 2017, 9, 1277-1294.	2.3	12
57	Advances and Challenges in Drug Design of PPARÎ´ Ligands. Current Drug Targets, 2018, 19, 144-154.	2.1	11
58	Purification, crystallization and preliminary X-ray analysis of the aspartate aminotransferase ofPlasmodium falciparum. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 409-412.	0.7	10
59	Targeting the Plasmodium falciparum plasmepsin V by ligandâ€based virtual screening. Chemical Biology and Drug Design, 2019, 93, 300-312.	3.2	10
60	Insights in Chloroquine Action: Perspectives and Implications in Malaria and <scp>COVID</scp>â€19. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 872-881.	1.5	10
61	The activity of Plasmodiumâ€ffalciparum arginase is mediated by a novel interâ€monomer saltâ€bridge between Glu295â€“Arg404. FEBS Journal, 2009, 276, 3517-3530.	4.7	9
62	Insights into the genome and secretome of Fusarium metavorans DSM105788 by cultivation on agro-residual biomass and synthetic nutrient sources. Biotechnology for Biofuels, 2021, 14, 74.	6.2	9
63	Drug Target Validation Methods in Malaria - Protein Interference Assay (PIA) as a Tool for Highly Specific Drug Target Validation. Current Drug Targets, 2017, 18, 1069-1085.	2.1	9
64	Purification, crystallization and preliminary X-ray diffraction analysis of the thiaminase type II fromStaphylococcus aureus. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 51-53.	0.7	8
65	Identification and Validation of Novel Drug Targets for the Treatment of Plasmodium falciparum Malaria: New Insights. , 0, , .		8
66	Current trends in quantitative structureâ€“activity relationship validation and applications on drug discovery. Future Science OA, 2017, 3, FSO214.	1.9	8
67	Mobility of the conserved glycine 155 is required for formation of the active plasmodial Pdx1 dodecamer. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 347-350.	2.4	7
68	Cytometric quantification of singlet oxygen in the human malaria parasite Plasmodium falciparum. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 698-703.	1.5	7
69	Identification of Aptamers as Specific Binders and Modulators of Cell-Surface Receptor Activity. Methods in Molecular Biology, 2013, 986, 17-39.	0.9	7
70	Structure of ThiM from Vitamin B1 biosynthetic pathway of Staphylococcus aureus â€“ Insights into a novel pro-drug approach addressing MRSA infections. Scientific Reports, 2016, 6, 22871.	3.3	7
71	Molecular Target Validation of Aspartate Transcarbamoylase from Plasmodium falciparum by Torin 2. ACS Infectious Diseases, 2020, 6, 986-999.	3.8	7
72	New directions in antimalarial target validation. Expert Opinion on Drug Discovery, 2020, 15, 189-202.	5.0	7

#	Article	IF	Citations
73	Staphylococcus aureusthiaminase II: oligomerization warrants proteolytic protection against serine proteases. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 2320-2329.	2.5	6
74	Plasmodium falciparum GFP-E-NTPDase expression at the intraerythrocytic stages and its inhibition blocks the development of the human malaria parasite. Purinergic Signalling, 2017, 13, 267-277.	2.2	6
75	Live and Let Dye: Visualizing the Cellular Compartments of the Malaria Parasite Plasmodium falciparum. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 694-705.	1.5	6
76	Targeting SUMOylation in Plasmodium as a Potential Target for Malaria Therapy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 685866.	3.9	6
77	Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon. PLoS ONE, 2021, 16, e0253752.	2.5	6
78	MALDI-TOF mass spectrometry of saliva samples as a prognostic tool for COVID-19. Journal of Oral Microbiology, 2022, 14, 2043651.	2.7	6
79	On the relationship of anthranilic derivatives structure and the FXR (Farnesoid X receptor) agonist activity. Journal of Biomolecular Structure and Dynamics, 2018, 36, 4378-4391.	3.5	5
80	The thermal proteome stability profile of Trypanosoma cruzi in epimastigote and trypomastigote life stages. Journal of Proteomics, 2021, 248, 104339.	2.4	5
81	Metabolite Transporters in Trypanosomatid Parasites: Promising Therapeutic Targets Butâ€¦ How to Deal with Them?. Current Medicinal Chemistry, 2014, 21, 1707-1712.	2.4	5
82	Crystallization and preliminary X-ray diffraction of malate dehydrogenase fromPlasmodium falciparum. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 659-662.	0.7	4
83	Purification, crystallization and preliminary X-ray diffraction analysis of pyridoxal kinase fromPlasmodium falciparum(PfPdxK). Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 1550-1555.	0.8	4
84	Nuclear Receptor Modulators â€" Current Approaches and Future Perspectives. , 2015, , .		4
85	Identification of a non-competitive inhibitor of Plasmodium falciparum aspartate transcarbamoylase. Biochemical and Biophysical Research Communications, 2018, 497, 835-842.	2.1	4
86	Oligomeric protein interference validates druggability of aspartate interconversion in Plasmodium falciparum. MicrobiologyOpen, 2019, 8, e779.	3.0	4
87	Modulating Fingolimod (FTY720) Anti-SARS-CoV-2 Activity Using a PLGA-Based Drug Delivery System. ACS Applied Bio Materials, 2022, 5, 3371-3383.	4.6	4
88	Purification, crystallization and preliminary X-ray diffraction analysis of ThiM fromStaphylococcus aureus. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 479-481.	0.7	3
89	Oxidative Stress in Human Infectious Diseases â€" Present and Current Knowledge About Its Druggability. , 2013, , .		3
90	Solution Structures and Dynamic Assembly of the 24-Meric Plasmodial Pdx1â€"Pdx2 Complex. International Journal of Molecular Sciences, 2020, 21, 5971.	4.1	3

#	Article	IF	Citations
91	The Crystal Structure of the Plasmodium falciparum PdxK Provides an Experimental Model for Pro-Drug Activation. Crystals, 2019, 9, 534.	2.2	2
92	Genome and Secretome Analysis of Staphylotrichum longicolleum DSM105789 Cultured on Agro-Residual and Chitinous Biomass. Microorganisms, 2021, 9, 1581.	3.6	2
93	Lipoic Acid Metabolism as a Potential Chemotherapeutic Target Against Plasmodium falciparum and Staphylococcus aureus. Frontiers in Chemistry, 2021, 9, 742175.	3.6	2
94	Novel Highlight in Malarial Drug Discovery: Aspartate Transcarbamoylase. Frontiers in Cellular and Infection Microbiology, 2022, 12, 841833.	3.9	2
95	Aptamers in Bacterial, Viral, and Parasitic Diseases. , 2017, , 169-186.		1
96	Transporter-Mediated Solutes Uptake as Drug Target in Plasmodium falciparum. Frontiers in Pharmacology, 2022, 13, 845841.	3.5	1
97	Structure and activity of the DHNA Coenzyme-A Thioesterase from Staphylococcus aureus providing insights for innovative drug development. Scientific Reports, 2022, 12, 4313.	3.3	1
98	Drug Discovery by Aptamers in Protozoan Infectious Diseases. , 2011, , .		0
99	Editorial (Thematic Issue: Drug Discovery for Infectious Agents Causing Neglected Diseases). Current Medicinal Chemistry, 2014, 21, 1667-1667.	2.4	0
100	Structure-function analysis of proteins involved in the metabolic pathway of vitamin K acting as major pathogenic factors inStaphylococcus aureusinfection. Acta Crystallographica Section A: Foundations and Advances, 2015, 71, s261-s261.	0.1	0
101	Structural Dynamics and Perspectives of Vitamin B6 Biosynthesis Enzymes in Plasmodium: Advances and Open Questions. Frontiers in Cellular and Infection Microbiology, 2021, 11, 688380.	3.9	0
102	Structure of the essential enzyme ThiM from the bacteriumStaphylococcus aureus. Acta Crystallographica Section A: Foundations and Advances, 2010, 66, s146-s147.	0.3	0
103	Vitamin Metabolism in the Malaria Parasite. , 2013, , 1-7.		0
104	Structural and biophysical analysis of the pyridoxal phosphate synthase from Plasmodium vivax. Acta Crystallographica Section A: Foundations and Advances, 2019, 75, e59-e59.	0.1	0
105	Mechanism of Drug Resistance in Staphylococcus aureus and Future Drug Discovery. , 2020, , 259-280.		0
106	Editorial: From Apicomplexan Genes to Drug Discovery. Frontiers in Cellular and Infection Microbiology, 2021, 11, 798754.	3.9	0